These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 11872356)
1. HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia. St'astný M; Plocová D; Etrych T; Ulbrich K; Ríhová B Eur J Cancer; 2002 Mar; 38(4):602-8. PubMed ID: 11872356 [TBL] [Abstract][Full Text] [Related]
2. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy. St'astný M; Plocová D; Etrych T; Kovár M; Ulbrich K; Ríhová B J Control Release; 2002 May; 81(1-2):101-11. PubMed ID: 11992683 [TBL] [Abstract][Full Text] [Related]
3. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. St'astný M; Strohalm J; Plocová D; Ulbrich K; Ríhová B Eur J Cancer; 1999 Mar; 35(3):459-66. PubMed ID: 10448300 [TBL] [Abstract][Full Text] [Related]
4. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility. Ríhová B; Srogl J; Jelínková M; Hovorka O; Buresová M; Subr V; Ulbrich K Ann N Y Acad Sci; 1997 Dec; 831():57-71. PubMed ID: 9616702 [TBL] [Abstract][Full Text] [Related]
5. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412 [TBL] [Abstract][Full Text] [Related]
6. Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro. Subr V; Sivák L; Koziolová E; Braunová A; Pechar M; Strohalm J; Kabešová M; Ríhová B; Ulbrich K; Kovář M Biomacromolecules; 2014 Aug; 15(8):3030-43. PubMed ID: 24978588 [TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. Sivak L; Subr V; Tomala J; Rihova B; Strohalm J; Etrych T; Kovar M Biomaterials; 2017 Jan; 115():65-80. PubMed ID: 27886555 [TBL] [Abstract][Full Text] [Related]
8. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel. Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304 [TBL] [Abstract][Full Text] [Related]
9. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia. Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020 [TBL] [Abstract][Full Text] [Related]
10. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice. Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307 [TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Krishna R; Mayer LD Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743 [TBL] [Abstract][Full Text] [Related]
12. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor. Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin. Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491 [TBL] [Abstract][Full Text] [Related]
14. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. Yang Z; Yu S; Li D; Gong Y; Zang J; Liu J; Chen X Colloids Surf B Biointerfaces; 2018 Dec; 172():387-394. PubMed ID: 30193198 [TBL] [Abstract][Full Text] [Related]
15. A novel α Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244 [TBL] [Abstract][Full Text] [Related]
16. Injectable small molecule hydrogel as a potential nanocarrier for localized and sustained in vivo delivery of doxorubicin. Singh M; Kundu S; Reddy M A; Sreekanth V; Motiani RK; Sengupta S; Srivastava A; Bajaj A Nanoscale; 2014 Nov; 6(21):12849-55. PubMed ID: 25227567 [TBL] [Abstract][Full Text] [Related]
17. Supramolecular hydrogels as a universal scaffold for stepwise delivering Dox and Dox/cisplatin loaded block copolymer micelles. Zhu W; Li Y; Liu L; Chen Y; Xi F Int J Pharm; 2012 Nov; 437(1-2):11-9. PubMed ID: 22902390 [TBL] [Abstract][Full Text] [Related]
18. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482 [TBL] [Abstract][Full Text] [Related]
20. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer. Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]